| abstract |
(57) [Summary]nThe present invention generally provides pharmaceutical compositions of salicylanilide inhibitors of the transcription factor NF-κB, and methods of treating diseases involving NF-κB activation. More particularly, the invention relates to inflammatory disorders, in particular rheumatoid arthritis, inflammatory bowel disease and asthma; skin diseases such as psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; Atherosclerosis; restenosis; cancer, including Hodgkin's disease; and certain viral infections, including activation of NF-κB, including AIDS; osteoarthritis; osteoporosis; A method for treating various diseases associated with the above, which comprises administering a compound of the present invention to a patient in need of such treatment. |